Rekombinanter TNF alpha (Infliximab Biosimilar) Antikörper

Produktnummer ABIN7200661

Dieses Anti-TNF alpha (Infliximab Biosimilar)-Antikörper ist ein Maus Monoklonal-Antikörper zur Detektion von TNF alpha (Infliximab Biosimilar) in FACS und in vivo. Geeignet für Human.

Kurzübersicht für Rekombinanter TNF alpha (Infliximab Biosimilar) Antikörper (ABIN7200661)

Target: TNF alpha (Infliximab Biosimilar)

Antikörpertyp: Recombinant Antibody

Reaktivität: Human

Wirt: Maus

Klonalität: Monoklonal

Konjugat: Dieser TNF alpha (Infliximab Biosimilar) Antikörper ist unkonjugiert

Applikation: Flow Cytometry (FACS), In vivo Studies (in vivo)

Klon: CA2

Produktdetails anti-TNF alpha (Infliximab Biosimilar) Antikörper

Verwendungszweck: Infliximab Biosimilar, TNF alpha Monoclonal Antibody

Spezifität: The monoclonal antibody Infliximab biosimilar specifically binds to the human TNF alpha.

Produktmerkmale: Recombinant Chimeric IgG1 Monoclonal Antibody.

Aufreinigung: Protein A affinity column

Reinheit: > 95% by SDS-PAGE under reducing conditions and HPLC.

Sterilität: 0.2 μm filtered

Endotoxin-Niveau: < 1 EU per 1 mg of the protein by the LAL method.

Immunogen: The monoclonal antibody Infliximab biosimilar was produced in the Infliximab biosimilar CHO stable cell line.

Isotyp: IgG1 kappa

Anwendungsinformationen

Applikationshinweise: ELISA, neutralization, functional assays such as bioanalytical PK and ADA assays, and those assays for studying biological pathways affected by Infliximab.

Beschränkungen: Nur für Forschungszwecke einsetzbar

Handhabung

Format: Liquid

Konzentration: 1 mg/mL

Buffer: PBS, pH 7.4, no stabilizers or preservatives.

Konservierungsmittel: Without preservative

Handhabung: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.

Lagerung: -20 °C

Informationen zur Lagerung: 12 months from date of receipt, -20 to -70°C as supplied. 1 month from date of receipt, 2 to 8°C as supplied.

Haltbarkeit: 12 months

Details zu TNF alpha (Infliximab Biosimilar)

Target: TNF alpha (Infliximab Biosimilar)

Substanzklasse: Biosimilar

Hintergrund: Infliximab, a chimeric anti-TNF-α monoclonal antibody, is used to treat psoriasis, Crohn's disease, ankylosing spondylitis, psoriatic arthritis, rheumatoid arthritis, and ulcerative colitis. Infliximab interferes TNF-α from binding to its receptor in the cell.

Mainly produced by activated macrophages (M1), Tumor necrosis factor (TNF, cachexin, cachectin, tumor necrosis factor alpha, TNFα) plays important roles in the regulation of autoimmune reaction.